TABLE 3

Influence of the diagnostic criteria on the time in days to diagnosis of AKI during intravenous AmB use in 162 hospitalized adults treated at a university hospital, stratified by type of AmB preparation

AKI criteria (n)aAll (n = 162) (median [IQR])Type of AmB preparation (median [IQR])
Deoxycholate (n = 120)Liposomal (n = 42)
NT0.5 (73)6.0 (4.0 to 9.0)5.0 (4.0 to 9.0)7.0 (4.0 to 12.5)
NT2× (45)5.0 (3.0 to 8.0)5.0 (3.0 to 980)6.0 (4.0 to 8.0)
KDIGO stageb
    1 (76)4.0 (2.0 to 7.8)4.0 (2.5 to 7.5)4.0 (2.0 to 8.0)
    2 (40)5.5 (3.3 to 8.0)5.5 (3.0 to 8.3)5.5 (3.5 to 8.8)
    3 (15)7.0 (4.0 to 13.0)7.0 (3.5 to 13.0)8.0 (6.0 to 10.0)
  • a NT2×, traditional nephrotoxicity criterion of an SCr increase of ≥2× over baseline; NT0.5, traditional nephrotoxicity criterion of an absolute SCr increase of ≥0.5 mg/dl over baseline; KDIGO, Kidney Diseases Improving Global Outcomes.

  • b The number of patients with AKI by the KDIGO criteria was 95. The sum of patients across the KDIGO stages add up to >95 because some patients progressed from stage 1 to stages 2 and 3 during treatment.